Company Encyclopedia
View More
name
WAI YUEN TONG
00897.HK
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, engages in production and sale of Chinese and western pharmaceuticals and health food products in Mainland China and Hong Kong. The company manufactures, processes, and sells traditional Chinese medicines under the brand Wai Yuen Tong brand and western pharmaceutical and personal care products under the Madame Pearl’s and Pearl’s brands. It also invests in commercial premises for rental. Wai Yuen Tong Medicine Holdings Limited was founded in 1897 and is headquartered in Kowloon Bay, Hong Kong.
1.450 T
00897.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking42/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.16%D
    • Profit Margin-1.92%D
    • Gross Margin51.20%B
  • Growth ScoreD
    • Revenue YoY-5.39%D
    • Net Profit YoY-388.34%E
    • Total Assets YoY-4.76%D
    • Net Assets YoY-1.42%D
  • Cash ScoreE
    • Cash Flow Margin-5215.65%E
    • OCF YoY-5.39%D
  • Operating ScoreC
    • Turnover0.42C
  • Debt ScoreB
    • Gearing Ratio30.07%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "WAI YUEN TONG" mid-term net profit of HKD 2.77 million fell by 88% and no dividend is declared

    WAI YUEN TONG announced its interim results for the six months ending in September, with revenue of HKD 323 million, a year-on-year decrease of 6.9%. It recorded a net profit of HKD 2.77 million, a decline of 88.3%, with earnings per share of 0.25 cents. No dividend was declared

    AASTOCKS·
    HK
    00897
    0.00%
    AASTOCKS·
    HK
    00897
    0.00%

    Wai Yuen Tong Medicine Holdings revenue falls 6.9% with profit down 88.2%

    Wai Yuen Tong Medicine Holdings Limited reported a 6.9% decrease in revenue to HK$322.8 million for the six months ending September 30, 2025. Gross profit fell by 9.2% to HK$165.3 million, and profit attributable to owners dropped 88.2% to HK$2.8 million. Earnings per share decreased to 0.25 HK cents from 2.10 HK cents. The company's net asset value was HK$1,181.5 million, with cash and cash equivalents at HK$121.2 million. The company focuses on Chinese pharmaceutical and health food products, mainly in Mainland China and Hong Kong.

    Reuters·
    HK
    00897
    0.00%
    Reuters·
    HK
    00897
    0.00%

    News: WAI YUEN TONG forecasts a nearly 90% year-on-year decline in interim profits

    WAI YUEN TONG Pharmaceutical Holdings Limited issued a profit warning, expecting that the interim net profit for the period ending September will not exceed HKD 3 million, a year-on-year decrease of 87%. The company stated that the decline in consumer willingness at the retail end led to a revenue decrease of approximately 7%, a reduction in gross profit, and a decline in the net fair value gains of investment properties were also reasons for the profit drop. Some negative impacts were offset by a decrease in administrative expenses and financing costs

    BambooWorks·
    HK
    00897
    0.00%
    BambooWorks·
    HK
    00897
    0.00%

    "Waning Profit Warning" WAI YUEN TONG forecasts that mid-term net profit will decrease to no more than 3 million yuan

    WAI YUEN TONG issued a profit warning, expecting a net profit of no more than HKD 3 million for the six months ending in September, compared to HKD 23.7 million in the same period last year. The decrease in profit is mainly due to weak consumer demand in the retail market during the period, resulting in a revenue decline of approximately 7%, with gross profit correspondingly decreasing; the net income from property sales significantly decreased; and the fair value gains from investment properties decreased

    AASTOCKS·
    HK
    00897
    0.00%
    AASTOCKS·
    HK
    00897
    0.00%

    Wai Yuen Tong Medicine Warns of Lower Fiscal H1 Profit

    Wai Yuen Tong Medicine Warns of Lower Fiscal H1 Profit

    marketscreener·
    HK
    00897
    0.00%
    marketscreener·
    HK
    00897
    0.00%
    © 2025 Longbridge｜Disclaimer